

Factor VIII Concentrates
Effective 01/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Hemophilia A (factor VIII [factor 8] deficiency) and hemophilia B (factor IX [factor 9] deficiency) are X-linked inherited coagulation factor deficiencies that result in lifelong bleeding disorders.

Factor VIII products are used to control and prevent bleeding episodes in adults and children with Hemophilia A, for perioperative management in adults and children with Hemophilia A, and for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with Hemophilia A.

Preferred Products	Non-Preferred Products
Advate	Alphanate
Adynovate	Hemofil M
Afstyla	Humate-P
Altuviiio	
Eloctate	
Esperoct	
Jivi	
Kovaltry	
Koate	
Kogenate FS	
Novoeight	
Nuwiq	
Recombinate	
Xyntha	
Xyntha Solofuse	

Coverage Guidelines

Authorization may be granted for members new to the plan within the last 90 days who are currently receiving treatment with the requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Hemophilia A

Authorization may be granted for the following preferred products: Advate, Adynovate, Afstyla, Altuviiio, Eloctate, Esperoct, Koate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, or Xyntha Solofuse, when #1 or #2 are met:

1. Member has mild disease (see Appendix A) and has had an insufficient response to desmopressin or a documented clinical reason for not using desmopressin (see Appendix B).
2. Member has moderate or severe disease (see Appendix A).
3. Authorization of a **non-preferred product** requires the member meet #1 or #2 as well as documentation that the member has had an inadequate response or intolerance to one preferred product or clinical rationale why none of the preferred products is appropriate for the member

Authorization of **Jivi** may be granted for treatment of hemophilia A if **ONE** of the following criteria are met:

1. Member has mild disease (see Appendix A) and has had an insufficient response to desmopressin or a documented clinical reason for not using desmopressin (see Appendix B)
2. Member has moderate or severe disease (see Appendix A)
3. Member has previously received treatment for hemophilia A with a factor VIII product **AND** the member is 7 years of age or older

Von Willebrand Disease (VWD)

Authorization of Alphanate, Humate-P, or Koate may be granted for treatment of VWD when any of the following criteria is met:

1. Member has type 1, 2A, 2M, or 2N VWD and has had an insufficient response to desmopressin or a documented clinical reason for not using desmopressin (see Appendix B).
2. Member has type 2B or type 3 VWD.

Acquired Hemophilia A

1. Authorization of Advate, Adynovate, Afstyla, Altuviiio, Eloctate, Esperoct, Koate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Xyntha Solofuse and Jivi may be granted for treatment of acquired hemophilia A.
2. Authorization of a non-preferred product requires the member meet #1 and documentation that the member has had an inadequate response or intolerance to one preferred product or clinical rationale why none of the preferred products is appropriate for the member

Acquired von Willebrand Syndrome

Authorization of Alphanate or Humate-P may be granted for treatment of acquired von Willebrand syndrome.

Continuation of Therapy

Reauthorization may be granted when the following criteria are met:

1. Initial criteria has been met
2. Member is experiencing a positive response to therapy (e.g., reduced frequency or severity of bleeds).



Limitations

Approvals will be granted for 36 months.

APPENDICES

Appendix A: Classification of Hemophilia by Clotting Factor (% activity) and Bleeding Episodes

Bleeding Episodes Severity	Clotting Factor Level % activity*	Bleeding Episodes
Severe	< 1%	Spontaneous bleeding episodes, predominantly into joints and muscles Severe bleeding with trauma, injury or surgery
Moderate	1% to 5%	Occasional spontaneous bleeding episodes. Severe bleeding with trauma, injury or surgery
Mild	6% to 40%	Severe bleeding with serious injury, trauma or surgery

Appendix B: Clinical Reasons For Not Utilizing Desmopressin in Patients with Hemophilia A and Type 1, 2A, 2M and 2N (VWD)

- A. Age < 2 years
- B. Pregnancy
- C. Fluid/electrolyte imbalance
- D. High risk for cardiovascular or cerebrovascular disease (especially the elderly)
- E. Predisposition to thrombus formation
- F. Trauma requiring surgery
- G. Life-threatening bleed
- H. Contraindication or intolerance to desmopressin
- I. Severe type 1 von Willebrand disease

References

1. Acquired hemophilia. World Federation of Hemophilia. <http://www1.wfh.org/publications/files/pdf-1186.pdf>. Accessed December 12, 2019.
2. Advate [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA, Inc; March 2023.
3. Adynovate [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA, Inc; August 2023.
4. Afstyla [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2023.
5. Alphanate [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc.; November 2022.
6. Altuviiio [prescribing information]. Waltham, MA: Bioverativ Therapeutics Inc.; March 2025.
7. Brand B, Gruppo R, Wynn TT, et al. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients. *Haemophilia* 2016; 22:e251.
8. Eloctate [prescribing information]. Waltham, MA: Bioverativ Therapeutics Inc.; May 2023.
9. Escobar MA, Brewer A, Caviglia H, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. *Haemophilia* 2018; 24:693.
10. Esperoct [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; July 2024.



11. Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. *Thromb Haemost*. 2013;110(6):1114-20.
12. Hemofil M [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals USA, Inc.; February 2025.
13. Humate-P (antihemophilic factor/von Willebrand factor complex) [prescribing information]. Kankakee, IL: CSL Behring; June 2020.
14. Huth-Kuhne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. *Haematologica*. 2009;94(4):566-75.
15. Jivi [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2025.
16. Koate [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc.; January 2022.
17. Kogenate FS [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; December 2019.
18. Kovaltry [prescribing information]. Whippany, NJ: Bayer Healthcare LLC; December 2022.
19. Leissinger C, Carcao M, Gill JC, et al. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. *Haemophilia*. 2014; 20:158-167.
20. Mannucci PM. Treatment of Hemophilia - More Amazing Progress. *N Engl J Med* 2020; 383:1068
21. National Hemophilia Foundation. Hemophilia A (Factor VIII Deficiency). Available at: <http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=180&contentid=45&rptname=bleeding>. Accessed December 12, 2019.
22. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised April 2018. MASAC Document # 253. <https://www.hemophilia.org/sites/default/files/document/files/masac253.pdf>. Accessed December 12, 2019.
23. National Hemophilia Foundation. MASAC recommendations regarding the treatment of von Willebrand disease. Revised November 2016. MASAC Document #244
24. Novoeight [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc.; July 2020.
25. Nuwiq [prescribing information]. Paramus, NJ: Octapharma USA, Inc.; December 2024.
26. Peyvandi F, Mamaev A, Wang JD, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. *J Thromb Haemost* 2019; 17:52.
27. Recombinate (antihemophilic factor [recombinant]) [prescribing information]. Lexington MA: Takeda Pharmaceuticals USA, LLC; March 2023.
28. Reding MT, NG HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. *Journal of thrombosis and Haemostasis*. 2017; 15: 411-9.
29. Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. *Blood* 2015; 125:907.. <https://www.hemophilia.org/sites/default/files/document/files/masac244.pdf>. Accessed December 12, 2019.
30. Xyntha [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; July 2022.
31. Xyntha Solufuse [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; July 2022.

Review History

11/18/2020-Updated: Moved from SGM to custom template, added preferred drug strategy, changed approval duration from indefinite to 36 months, references updated; P+T review

03/17/2021 – Updated and reviewed; Removed Monoclate-P and Helixate FS from criteria as products have been discontinued; references updated. Effective 06/01/2021.

11/16/2022 – Reviewed and Updated for Nov P&T. Updated preferred and non-preferred products. Preferred products include: Advate, Afystyla, Kovaltry, Novoeight, Nuwiq, Xyntha, Xyntha Solofuse and Jivi. Effective 01/01/2023.

06/14/2023 – Updated and reviewed for June P&T; Added new drug Altuvio to criteria as a non-preferred agent. Effective 8/1/2023



07/10/2024 – Updated and reviewed for July P&T; Updated criteria to move Recombinate, Altuviiio, Koate, Eloctate, and Esperoct to preferred status; Updated criteria for nonpreferred products to require step through with one preferred agent or clinical rationale why none of the preferred agents is clinically appropriate; Clarified that members are considered new to the Plan if they joined within the previous 90 days; Effective 09/01/2024.

04/09/2025 – Reviewed and updated for April P&T. Updated reauthorization criteria to require member has had a positive response to therapy. Effective 07/01/2025.

07/09/2025 – Reviewed and updated at July P&T. Updated age for Jivi from 12 years to 7 years to align with updated FDA-approval. Moved Kogenate FS to preferred status in the approval criteria. Effective 10/01/2025.

10/08/2026 – Reviewed and updated at October P&T. Updated policy to indicate it no longer applies to the medical benefit. Effective 01/01/2026.

